Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer

Completed · Phase 1

Conditions studied: NON-breast HER2+ Malignancies

In brief

A first-in-human study using NJH395 in non-breast HER2-positive advanced malignancies

Key facts

Study ID

NCT03696771

Run by

Novartis Pharmaceuticals

People needed

18

Starts

2018-12-27

Expected to finish

2020-10-19

Last updated by the study team

2022-02-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Texas MD Anderson Cancer Center — Houston, Texas, United States
• Novartis Investigative Site — Milan, MI, Italy
• Novartis Investigative Site — Kashiwa, Chiba, Japan
• Novartis Investigative Site — Seoul, South Korea

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.